HLA-DRB1 and peanut allergic reaction: The peptides identified in the present study offer potential for epitope-based immunotherapy targeting HLA-DRB1*03:01-restricted peanut allergy patients, potentially reducing the risk of irrelevant protein targeting and minimizing undesirable immune responses.